KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) EBT Margin (2017 - 2026)

Twist Bioscience has reported EBT Margin over the past 10 years, most recently at 39.72% for Q1 2026.

  • Quarterly EBT Margin rose 247.0% to 39.72% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 19.67% through Mar 2026, up 3521.0% year-over-year, with the annual reading at 20.43% for FY2025, 4608.0% up from the prior year.
  • EBT Margin was 39.72% for Q1 2026 at Twist Bioscience, down from 29.18% in the prior quarter.
  • Over five years, EBT Margin peaked at 21.43% in Q2 2025 and troughed at 126.37% in Q1 2022.
  • The 5-year median for EBT Margin is 59.98% (2023), against an average of 63.17%.
  • Year-over-year, EBT Margin plummeted -1574bps in 2024 and then skyrocketed 12623bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 76.96% in 2022, then increased by 22bps to 59.98% in 2023, then soared by 41bps to 35.5% in 2024, then rose by 18bps to 29.18% in 2025, then tumbled by -36bps to 39.72% in 2026.
  • Per Business Quant, the three most recent readings for TWST's EBT Margin are 39.72% (Q1 2026), 29.18% (Q4 2025), and 27.15% (Q3 2025).